Integra Lifesciences Holdings (IART) Research & Development (2009 - 2026)

Integra Lifesciences Holdings has disclosed Research & Development across 18 years of filings, most recently posting $24.3 million for Q2 2026.

• In Q2 2026, Research & Development fell 10.16% year-over-year to $24.3 million; the TTM figure through Jun 2026 stood at $95.0 million (down 13.93% YoY), while the FY2025 annual figure was $99.0 million, down 14.22% from the prior year.
• Research & Development came in at $24.3 million for Q2 2026 at Integra Lifesciences Holdings, up from $23.5 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $31.2 million in Q4 2024 to a low of $22.5 million in Q3 2025.
• Average Research & Development over 5 years is $26.0 million, with a median of $26.1 million recorded in 2022.
• Year-over-year, Research & Development grew 28.52% in 2024 and decreased 20.57% in 2025.
• Over 5 years, Research & Development stood at $26.8 million in 2022, then declined by 9.33% to $24.3 million in 2023, then rose by 28.52% to $31.2 million in 2024, then decreased by 20.57% to $24.8 million in 2025, then declined by 2.17% to $24.3 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $24.3 million in Q2 2026, $23.5 million in Q1 2026, and $24.8 million in Q4 2025.